The startup produces and markets reagents protected by international patents that significantly reduce the time and cost of genetic diagnostic tests in oncology. These reagents are used by hospitals, research centers, and diagnostic laboratories: every year, hospital facilities have to treat 15 million new patients. The size of the global reagents market is substantial (almost $2B), as is the expected growth rate (9% per year).